about
Non-surgical interventions for treating heavy menstrual bleeding (menorrhagia) in women with bleeding disordersNon-surgical interventions for treating heavy menstrual bleeding (menorrhagia) in women with bleeding disordersEffect of vaccine administration modality on immunogenicity and efficacy.Immunogenicity to biologics: mechanisms, prediction and reduction.Transmission electron microscopy as an orthogonal method to characterize protein aggregates.Immunogenicity of different stressed IgG monoclonal antibody formulations in immune tolerant transgenic mice.The protein science of biosimilars.Polymer-based sustained-release dosage forms for protein drugs, challenges, and recent advancesImmunogenicity of subcutaneously administered therapeutic proteins--a mechanistic perspective.Effect of route of administration of human recombinant factor VIII on its immunogenicity in Hemophilia A miceBiopharmaceuticals from plants: a multitude of options for posttranslational modifications.Fabry disease, enzyme replacement therapy and the significance of antibody responses.Etanercept-induced injection site reactions: potential pathomechanisms and clinical assessment.Non-surgical interventions for treating heavy menstrual bleeding (menorrhagia) in women with bleeding disorders.Structural characterization of IgG1 mAb aggregates and particles generated under various stress conditions.Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study.Safety and efficacy of thrombin-JMI: a multidisciplinary expert group consensus.Immunogenicity issues in drug development.Correlation between HLA haplotypes and the development of antidrug antibodies in a cohort of patients with rheumatic diseases.Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far.Flow microscopy imaging is sensitive to characteristics of subvisible particles in peginesatide formulations associated with severe adverse reactions.Erythropoiesis equivalence, pharmacokinetics and immune response following repeat hematide administration in cynomolgus monkeys.
P2860
Q24187838-514A2DD5-4E96-4E90-9992-5FB1380D22FCQ24201889-A2733946-77FD-4DA2-9898-F0F5A77493C8Q27692376-09ED2BDE-77A9-413E-8C37-B026699A99D8Q34296526-93741B08-5577-4432-B4C6-DC253D937B57Q35224074-A10B531B-2379-4EA5-A8AB-F10D5768111DQ36411853-9856DC2B-AC56-43A8-AA26-3C4D998DA1FCQ36588724-6CA71EFB-DC6F-4F89-9622-D0461B82FC0CQ37065943-42CAFED7-1578-414E-81F9-FC733E539E18Q37207756-65D6424F-37E7-4CAE-BAEB-9BB38C6534ACQ37485765-1C006FA7-4041-431F-B524-BC4E1D5C8255Q37853856-7C061801-AB4F-45C0-8355-FC842B646ECAQ37950838-5302C81A-7C87-4DFA-8295-5137A421DD4EQ38045471-A47FA717-E0D8-4FAF-9DF3-2A3587F2F83AQ39007632-BC55103A-1740-4366-BA80-61840044FF2CQ40119636-07D2958C-5B67-4A58-AEEE-35D7738A85E5Q42674160-7FC06CD5-0E74-4C12-8972-70AA6E7C9327Q46070437-3A1F43C8-E50E-4FC3-8597-3AE69B07D389Q46717338-FDF43DDA-E95F-42D6-8A39-040E6A1FFCF5Q50073706-C190BA4E-6CDB-43D9-AE3B-DDEC474F0E6BQ50083992-40D5E380-0106-49B4-AD4F-1F41C05424B1Q50153560-4A5F00AA-05A7-4AA9-864D-CC504CD1F6A7Q50581034-A3B57AA7-CC76-4C3A-9873-3E921F8FAF83
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Immunogenicity of therapeutic proteins.
@ast
Immunogenicity of therapeutic proteins.
@en
type
label
Immunogenicity of therapeutic proteins.
@ast
Immunogenicity of therapeutic proteins.
@en
prefLabel
Immunogenicity of therapeutic proteins.
@ast
Immunogenicity of therapeutic proteins.
@en
P2860
P356
P1476
Immunogenicity of therapeutic proteins.
@en
P2093
Huub Schellekens
P2860
P304
P356
10.1093/NDT/GFG164
P407
P577
2003-07-01T00:00:00Z